VC-backed Zymeworks rolls out New York and Toronto IPO

Vancouver, British Columbia-based biotherapeutics provider Zymeworks Inc has raised $58.5 million for its IPO after pricing its 4.5 million shares at $13 per share. The stock began trading April 28, 2017 on the New York Stock Exchange and on the Toronto Stock Exchange under the ticker symbol “ZYME.”Citigroup Global Markets Canada Inc., Barclays Capital Inc. and Wells Fargo Securities, LLC are the lead underwriters. Zymeworks’ pre-IPO backers include BDC Capital, Lumira Capital, CTI Life Sciences Fund, Fonds de solidarité FTQ, Perceptive Advisors, Teralys Capital, Northleaf Venture Catalyst Fund, Brace Pharma Capital and Merlin Nexus. PRESS RELEASE VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (“Zymeworks”) today announced the pricing of its initial public offering of 4,500,000 common shares at a price to the public of U.S.$13.00 per share. In addition, Zymeworks has granted the underwriters a 30-day over-allotment option to purchase up to an additional
Continue reading "VC-backed Zymeworks rolls out New York and Toronto IPO"

PE-backed NCS unveils IPO

Houston, Texas and Calgary-based NCS Multistage Holdings, a technology and services company specializing in multistage completions, has raised $161.5 million for its IPO after pricing its 9.5 million shares at $17 per share. The stock began trading April 28, 2017 on the NASDAQ under the ticker symbol “NCSM.” Credit Suisse, Citigroup and Wells Fargo Securities are serving as the lead underwriters. NCS is backed by Advent International. PRESS RELEASE HOUSTON–(BUSINESS WIRE)–NCS Multistage Holdings, Inc. (“NCS” or the “Company”) announced today the pricing of its initial public offering of 9,500,000 shares of its common stock at a public offering price of $17.00 per share. The Company’s shares are expected to begin trading on the NASDAQ Global Select Market on April 28, 2017 under the ticker symbol “NCSM.” In addition, the underwriters have been granted a 30-day option to purchase up to an additional 1,425,000 shares
Continue reading "PE-backed NCS unveils IPO"

VC-backed Appian Corp debuts IPO

Reston, Virginia-based Appian Corp, a business process management software company, has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. Appian plans on listing the stock on the NASDAQ under the ticker symbol “APPN.” Morgan Stanley, Goldman Sachs and Barclays Capital Inc are serving as the lead underwriters. Appian is backed by New Enterprise Associates and Novak Biddle Venture Partners. PRESS RELEASE Reston, VA. April 27, 2017 — Appian Corporation announced today that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its Class A common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Appian intends to list its Class A common
Continue reading "VC-backed Appian Corp debuts IPO"

U.S. software company Cloudera beats expectations in IPO, says source: Reuters

U.S. software company Cloudera Inc (CLDR.N) raised $225 million in an initial public offering on Thursday, a source familiar with the situation said, giving the company a market valuation of about $1.9 billion, a steep fall from the $4.1 billion it was once valued at in the private market. Investors including chip company Intel Corp (INTC.O) piled into Cloudera several years ago when a flood of money into private technology companies pushed valuations skyward. Cloudera said it priced its shares at $15, above its indicated range of $12 to $14, but still a far cry from the $30.92 a share that Intel paid in 2014. Cloudera will begin trading tomorrow on the New York Stock Exchange under the symbol “CLDR.” The source asked not to be named because the negotiations are confidential. Cloudera and Intel did not immediately respond to requests for comment.
Continue reading "U.S. software company Cloudera beats expectations in IPO, says source: Reuters"

Onex-backed Emerald Expositions goes public

Emerald Expositions Events Inc, which is backed by the Onex Group, has raised $263.5 million after pricing its 15.5 million shares at $17 per share. The stock began trading on the New York Stock Exchange under the ticker symbol “EEX.” Emerald Expositions is an operator of business-to-business trade shows in the U.S. PRESS RELEASE TORONTO, ONTARIO–(Marketwired – April 27, 2017) – All amounts in U.S. dollars unless otherwise stated Emerald Expositions Events, Inc. (“Emerald Expositions”) announced the pricing of its initial public offering of 15,500,000 shares of its common stock at a public offering price of $17.00 per share. Emerald Expositions is selling 10,333,333 of those shares and Onex Corporation (“Onex”) (TSX:ONEX) and its affiliates (the “Onex Group”) are selling 5,166,667 shares. The underwriters were granted a 30-day option to purchase up to 2,325,000 additional shares of common stock from the Onex
Continue reading "Onex-backed Emerald Expositions goes public"

Verona Pharma debuts IPO

London-based Verona Pharma, a biopharmaceutical company, has priced its IPO of over 5.8 million shares at $13.50 per share. The stock began trading April 27, 2017 on the NASDAQ under the ticker symbol “VRNA.” Jefferies and Stifel are serving as the lead underwriters. Verona Pharma’s backers include Vivo Capital, OrbiMed, New Enterprise Associates, Abingworth, Henderson Global Investors and Aisling Capital. PRESS RELEASE April 27, 2017, LONDON – Verona Pharma plc (AIM: VRP) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, announces today the pricing of its global offering of an aggregate of 47,399,001 new ordinary shares, comprising 5,768,000 American Depositary Shares (“ADSs”) at a price of $13.50 per ADS and 1,255,001 ordinary shares at a price of £1.32 per ordinary share, for aggregate proceeds of approximately $80.0
Continue reading "Verona Pharma debuts IPO"

PE-backed Floor & Decor goes public

Floor & Decor Holdings, a retailer of hard surface flooring and related accessories, went public after its IPO priced at about 8.82 million shares at $21 each. The stock began trading April 27, 2017 on the New York Stock Exchange under the ticker symbol “FND.” BofA Merrill Lynch, Barclays, Credit Suisse, UBS Investment Bank, Goldman Sachs, Jefferies, Piper Jaffray and Wells Fargo Securities are serving as the underwriters. Floor & Decor is backed by Freeman Spogli & Co and Ares Management. PRESS RELEASE ATLANTA–(BUSINESS WIRE)– Floor & Decor Holdings, Inc. (the “Company” or “Floor & Decor”)today announced the pricing of its initial public offering of 8,823,500 shares of its common stock at a price to the public of $21.00 per share. The shares are expected to begin trading on the New York Stock Exchange on April 27, 2017 under the symbol “FND.” In addition, Floor &
Continue reading "PE-backed Floor & Decor goes public"